Bicara therapeutics announces first patients enrolled in fortifi-hn01, a pivotal phase 2/3 clinical trial of ficerafusp alfa in 1l recurrent/metastatic head and neck squamous cell carcinoma

Boston, feb. 11, 2025 (globe newswire) -- bicara therapeutics inc. (nasdaq: bcax), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the first patients have been enrolled in fortifi-hn01, a pivotal phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1l (first line) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (hnscc). ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (egfr) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (tgf-Β).
BCAX Ratings Summary
BCAX Quant Ranking